New York, New York: The Tipline for 6 August 2020
“We’re in the midst of a pandemic” is an excuse that many of us have likely used over the past few months, but one generic drugmaker targeted in the Department of Justice’s price-fixing probe has cited the crisis as a reason for not settling with the agency. Teva Pharmaceuticals chief executive Kare Schultz told Bloomberg yesterday that his company would not sign a deferred prosecution agreement that might “cripple” its ability to supply drugs in the US during covid-19. Also in today’s Tipline, we have a proposed amendment to New York antitrust law that its sponsor says is intended to rein in titans of the technology business, plus the DOJ suing to block a hospital deal and a cartel defence lawyer moving firms.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10